The company previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Bayer will seek shareholder approval to raise equity capital worth close to 35% of its outstanding shares over the next three ...

Kennedy can provide doctors and healthcare professionals with the information they need to truly determine if a drug is safe, ...

Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

Jazz Pharmaceuticals acquires Chimerix (CMRX) for $935M, adding ONC201, a promising brain cancer drug. Find out why I believe ...

ARS Pharmaceuticals (SPRY) announced that the FDA has approved neffy 1 mg for the treatment of Type I Allergic Reactions, including ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on ...